The global viral vector manufacturing market accounted for USD 5.58 billion in 2023 and is expected to reach at USD 35.31 billion by 2034 with a CAGR of 18.26% during the forecast period 2024-2034. A significant progress in gene therapy, enhancements in manufacturing procedures, increased investments in cell & gene therapy research, rising use of suspension-based cell culture, growing adoption of single-use technology in vector production facilities, increasing emphasis on vaccine development, rise in mergers & acquisitions among industry participants, and surge in the introduction of new viral vector manufacturing platforms are the key factors propelling the market growth.
Surge in the introduction of new viral vector manufacturing platforms is predicted to boost the market growth during the forecast period. Viral vector manufacturing involves the production of viral vectors, which serve as vehicles for introducing genetic material into target cells for various applications such as gene therapy, vaccine creation, and research. Typically, these vectors are derived from naturally occurring viruses that have been modified to ensure their safety and utility in medical or scientific contexts. For instance, in November 2023, Yposkesi, the European clinical and commercial viral vector manufacturing subsidiary of SK Pharmteco for Cell and Gene Therapies (C>), has introduced AAVelocityTM, a plug-and-play platform for Adeno-Associated Virus (AAV). AAVelocity aims to enhance cost and time effectiveness for drug developers in producing AAV gene delivery systems, which are utilized to deliver gene therapy into tissues for the prevention, treatment, or cure of inherited disorders and rare diseases.
By disease, cancer was the highest revenue-grossing segment in the global viral vector manufacturing market in 2023 owing to the increase in the incidence of new cancer diagnoses, growing adoption of western lifestyle habits such as high alcohol consumption, smoking, unhealthy dietary habits, & lack of physical activity, rising demand for gene therapies to treat cancer patients, and increased need for viral vectors and plasmid DNA in the development of these therapies. For instance, in January 2024, Charles River Laboratories International, Inc. unveiled its ready-made Rep/Cap plasmid product, aimed at simplifying AAV-based gene therapy projects. Additionally, genetic disorders is predicted to grow at the fastest CAGR during the forecast period owing to the increase in the occurrence of genetic disorders, rise in the number of clinical trials, and growing emphasis on the advancement of gene therapies.
By vector type, adeno-associated virus (AAV) was the highest revenue-grossing segment in the global viral vector manufacturing market in 2023 owing to the heightened use of these viruses in clinical trials is attributed to their ability to deliver genes precisely to the targeted area and increased adoption particularly seen in trials focused on the development of orthopedic and ocular gene therapies, showcasing enhanced effectiveness & efficiency. Additionally, lentivirus is predicted to grow at the fastest CAGR during the forecast period owing to the rising utilization of lentiviral vectors in ongoing research endeavors, growing emphasis placed by the research industry on enhancing these vectors, and increase in the introduction of new platforms in this field. For instance, in September 2023, Charles River Laboratories International, Inc. introduced Lentivation, its lentiviral vector (LVV) manufacturing platform. This platform has the potential to shorten LVV manufacturing schedules for gene and gene-modified cell therapies by approximately 60%, resulting in a timeframe of less than seven months, as opposed to conventional manufacturing processes.
By workflow, downstream processing was the highest revenue-grossing segment in the global viral vector manufacturing market in 2023 owing to the surge in the need for clinical-grade viral vectors, which necessitates intricate procedures for refining and purifying final products and increasing emphasis on innovating cost-effective downstream processes to overcome the obstacles encountered in traditional lab-scale vector manufacturing. Additionally, upstream processing is predicted to grow at the fastest CAGR during the forecast period owing to rising advancements in product development, exemplified by innovations such as the ambr 15 microbioreactor system for streamlining high-throughput upstream process development and growing trend of introducing new platforms. For instance, in August 2022, Merck KGaA has launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform, providing a comprehensive viral vector manufacturing solution that encompasses AAV as well as lentiviral vectors.
By application, vaccinology was the highest revenue-grossing segment in the global viral vector manufacturing market in 2023 owing to the growing need for vaccines targeting a various disease, including cancer & infectious diseases, heightened focus on the research & development of novel vaccines, upsurge in government investment in vaccine development initiatives, and rising collaborations within market players. For instance, in January 2022, WuXi Vaccines, a top-tier Contract Development and Manufacturing Organization (CDMO) specializing in vaccines, has entered into a Letter of Intent (LOI) with Shanghai BravoBio Co., Ltd (“BravoBio”). This agreement signifies a long-term partnership aimed at expediting the development and commercial production of BravoBio’s vaccine pipeline, targeting challenges posed by infectious diseases. Additionally, cell therapy is predicted to grow at the fastest CAGR during the forecast period owing to rise in personalized cancer treatments, marked by the effectiveness of Chimeric Antigen Receptor (CAR)-based cell therapies in treating cancer and surge in the introduction of new platforms by market players.
By end-user, research institutes was the highest revenue-grossing segment in the global viral vector manufacturing market in 2023 owing to the research entities are actively engaged in endeavors aimed at enhancing vector production methods, rising number of collaborative research efforts, and increasing introduction of new programs by research institutes. For instance, in October 2023, Aiming to develop commercially viable manufacturing methods and analytical platforms for adeno-associated virus (AAV) gene therapy vectors, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) launched the Viral Vectors initiative. Additionally, pharmaceutical & biotechnology companies segment is predicted to grow at the fastest CAGR during the forecast period owing to growing introduction of cutting-edge therapies, rise in the number of gene therapy-focused research initiatives undertaken by pharmaceutical companies, and increase in the number of biotechnology firms utilizing vectors for therapeutic manufacturing.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing involvement of companies in gene & cell therapy research, rise in the number of contract development organizations, and growing introduction of highly innovative manufacturing technologies for production. For instance, in May 2022, Catalent Inc. introduced the UpTempo Virtuoso platform process, designed for the development and production of adeno-associated viral (AAV) vectors. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising advancements in the regulatory framework for cell-based research, uptick in the development & commercialization of new vaccines, rising demand for gene therapies, significant progress in biotechnology, increasing government initiatives to support these endeavors, and growing introduction of innovative platforms. For instance, in November 2023, South Korean conglomerate SK Group's contract development and manufacturing organization (CDMO), SK Pharmteco Co., has launched two new viral vector manufacturing platforms known as LentiSure and AAVelocity. These platforms are anticipated to streamline the production of cutting-edge cell and gene therapies (CGTs), resulting in time and cost savings.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Surge in the introduction of new viral vector manufacturing platforms is predicted to boost the market growth during the forecast period. Viral vector manufacturing involves the production of viral vectors, which serve as vehicles for introducing genetic material into target cells for various applications such as gene therapy, vaccine creation, and research. Typically, these vectors are derived from naturally occurring viruses that have been modified to ensure their safety and utility in medical or scientific contexts. For instance, in November 2023, Yposkesi, the European clinical and commercial viral vector manufacturing subsidiary of SK Pharmteco for Cell and Gene Therapies (C>), has introduced AAVelocityTM, a plug-and-play platform for Adeno-Associated Virus (AAV). AAVelocity aims to enhance cost and time effectiveness for drug developers in producing AAV gene delivery systems, which are utilized to deliver gene therapy into tissues for the prevention, treatment, or cure of inherited disorders and rare diseases.
By disease, cancer was the highest revenue-grossing segment in the global viral vector manufacturing market in 2023 owing to the increase in the incidence of new cancer diagnoses, growing adoption of western lifestyle habits such as high alcohol consumption, smoking, unhealthy dietary habits, & lack of physical activity, rising demand for gene therapies to treat cancer patients, and increased need for viral vectors and plasmid DNA in the development of these therapies. For instance, in January 2024, Charles River Laboratories International, Inc. unveiled its ready-made Rep/Cap plasmid product, aimed at simplifying AAV-based gene therapy projects. Additionally, genetic disorders is predicted to grow at the fastest CAGR during the forecast period owing to the increase in the occurrence of genetic disorders, rise in the number of clinical trials, and growing emphasis on the advancement of gene therapies.
By vector type, adeno-associated virus (AAV) was the highest revenue-grossing segment in the global viral vector manufacturing market in 2023 owing to the heightened use of these viruses in clinical trials is attributed to their ability to deliver genes precisely to the targeted area and increased adoption particularly seen in trials focused on the development of orthopedic and ocular gene therapies, showcasing enhanced effectiveness & efficiency. Additionally, lentivirus is predicted to grow at the fastest CAGR during the forecast period owing to the rising utilization of lentiviral vectors in ongoing research endeavors, growing emphasis placed by the research industry on enhancing these vectors, and increase in the introduction of new platforms in this field. For instance, in September 2023, Charles River Laboratories International, Inc. introduced Lentivation, its lentiviral vector (LVV) manufacturing platform. This platform has the potential to shorten LVV manufacturing schedules for gene and gene-modified cell therapies by approximately 60%, resulting in a timeframe of less than seven months, as opposed to conventional manufacturing processes.
By workflow, downstream processing was the highest revenue-grossing segment in the global viral vector manufacturing market in 2023 owing to the surge in the need for clinical-grade viral vectors, which necessitates intricate procedures for refining and purifying final products and increasing emphasis on innovating cost-effective downstream processes to overcome the obstacles encountered in traditional lab-scale vector manufacturing. Additionally, upstream processing is predicted to grow at the fastest CAGR during the forecast period owing to rising advancements in product development, exemplified by innovations such as the ambr 15 microbioreactor system for streamlining high-throughput upstream process development and growing trend of introducing new platforms. For instance, in August 2022, Merck KGaA has launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform, providing a comprehensive viral vector manufacturing solution that encompasses AAV as well as lentiviral vectors.
By application, vaccinology was the highest revenue-grossing segment in the global viral vector manufacturing market in 2023 owing to the growing need for vaccines targeting a various disease, including cancer & infectious diseases, heightened focus on the research & development of novel vaccines, upsurge in government investment in vaccine development initiatives, and rising collaborations within market players. For instance, in January 2022, WuXi Vaccines, a top-tier Contract Development and Manufacturing Organization (CDMO) specializing in vaccines, has entered into a Letter of Intent (LOI) with Shanghai BravoBio Co., Ltd (“BravoBio”). This agreement signifies a long-term partnership aimed at expediting the development and commercial production of BravoBio’s vaccine pipeline, targeting challenges posed by infectious diseases. Additionally, cell therapy is predicted to grow at the fastest CAGR during the forecast period owing to rise in personalized cancer treatments, marked by the effectiveness of Chimeric Antigen Receptor (CAR)-based cell therapies in treating cancer and surge in the introduction of new platforms by market players.
By end-user, research institutes was the highest revenue-grossing segment in the global viral vector manufacturing market in 2023 owing to the research entities are actively engaged in endeavors aimed at enhancing vector production methods, rising number of collaborative research efforts, and increasing introduction of new programs by research institutes. For instance, in October 2023, Aiming to develop commercially viable manufacturing methods and analytical platforms for adeno-associated virus (AAV) gene therapy vectors, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) launched the Viral Vectors initiative. Additionally, pharmaceutical & biotechnology companies segment is predicted to grow at the fastest CAGR during the forecast period owing to growing introduction of cutting-edge therapies, rise in the number of gene therapy-focused research initiatives undertaken by pharmaceutical companies, and increase in the number of biotechnology firms utilizing vectors for therapeutic manufacturing.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing involvement of companies in gene & cell therapy research, rise in the number of contract development organizations, and growing introduction of highly innovative manufacturing technologies for production. For instance, in May 2022, Catalent Inc. introduced the UpTempo Virtuoso platform process, designed for the development and production of adeno-associated viral (AAV) vectors. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising advancements in the regulatory framework for cell-based research, uptick in the development & commercialization of new vaccines, rising demand for gene therapies, significant progress in biotechnology, increasing government initiatives to support these endeavors, and growing introduction of innovative platforms. For instance, in November 2023, South Korean conglomerate SK Group's contract development and manufacturing organization (CDMO), SK Pharmteco Co., has launched two new viral vector manufacturing platforms known as LentiSure and AAVelocity. These platforms are anticipated to streamline the production of cutting-edge cell and gene therapies (CGTs), resulting in time and cost savings.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Disease, Vector Type, Workflow, Application, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Viral Vector Manufacturing Market Report 2023 - 2034
Viral Vector Manufacturing Market Analysis & Forecast by Disease 2023 - 2034 (Revenue USD Bn)
- Infectious Diseases
- Genetic Disorders
- Cancer
- Others
Viral Vector Manufacturing Market Analysis & Forecast by Vector Type 2023 - 2034 (Revenue USD Bn)
- Adeno-Associated Virus (AAV)
- Retrovirus
- Adenovirus
- Plasmids
- Lentivirus
- Others
Viral Vector Manufacturing Market Analysis & Forecast by Workflow 2023 - 2034 (Revenue USD Bn)
- Downstream Manufacturing
- Fill Finish
- Purification
- Upstream Manufacturing
- Vector Recovery/Harvesting
- Vector Amplification & Expansion
Viral Vector Manufacturing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Cell Therapy
- Vaccinology
- Gene Therapy
- Research Applications
- Antisense & RNAi Therapy
Viral Vector Manufacturing Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Research Institutes
- Pharmaceutical & Biopharmaceutical Companies
Viral Vector Manufacturing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Viral Vector Manufacturing Market: Disease Estimates & Trend Analysis
8. Viral Vector Manufacturing Market: Vector Type Estimates & Trend Analysis
9. Viral Vector Manufacturing Market: Workflow Estimates & Trend Analysis
10. Viral Vector Manufacturing Market: Application Estimates & Trend Analysis
11. Viral Vector Manufacturing Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Viral Vector Manufacturing Market
14. Europe Global Viral Vector Manufacturing Market
15. Asia Pacific Global Viral Vector Manufacturing Market
16. Latin America Global Viral Vector Manufacturing Market
17. MEA Global Viral Vector Manufacturing Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Merck KGaA
- Charles River Laboratories
- Wuxi Biologics
- RegenxBio Inc.
- Lonza
- Waisman Biomanufacturing
- FUJIFILM Diosynth Biotechnologies
- Miltenyi Biotec GmbH
- Thermo Fisher Scientific Inc.
- Batavia Biosciences
- Genezen laboratories
